Unleashing the
full potential of
existing medicines
Galenicap is a Belgian-Dutch privately held pharmaceutical development company focused on the development of improved versions of existing medicines, featuring enhanced efficacy or safety profiles, and potentially offering new therapeutic applications. Our mission is to deliver superior, cost-effective treatment alternatives to patients, while also presenting substantial opportunities for cost reduction to healthcare providers.
In contrast to typical 505(b)(2) projects, which are often characterized by minimal product innovation, our focus is on pioneering solutions with substantial potential for true clinical impact
Everyone counts
Our vision is to deliver improvements to the healthcare community by increasing access to affordable and more patient-tailored medicines.
At Galenicap, we are dedicated to advancing our commitment to responsible business practices. Our focus on key pillars such as social impact and strong governance, underscores our dedication to health access, equitable medicine pricing, transparent leadership, and fostering diversity and inclusion.
We are proud to say that all our team members, collaborators, partners and shareholders share our values.
Latest news & events
Galenicap enters into drug reformulation program with Dutch university
March 28, 2024
Hans Platteeuw, Galenicap's CSO, to give keynote at Spark Europe Webinar "What is Drug Repurposing and Why is it Relevant"
January 29, 2024
Galenicap enters into drug reformulation co-development agreement with Germany pharma company
January 21, 2024